Abstract Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of anticancer treatment with microtubule-targeted agents (MTAs). The frequency of severe CIPN, which can be dose limiting and even life threatening, varies widely among different MTAs. For example, paclitaxel induces a higher frequency of severe CIPN than does eribulin. Different MTAs also possess distinct mechanisms of microtubule-targeted action. Recently, we demonstrated that paclitaxel and eribulin differentially affect sciatic nerve axons, with paclitaxel inducing more pronounced neurodegenerative effects and eribulin inducing greater microtubule stabilizing biochemical effects. Here, we complement and extend these axonal studies by assessing the effects of paclitaxel and eribulin in the cell bodies of sciatic nerve axons, housed in the dorsal root ganglia (DRG). Importantly, the microtubule network in cell bodies is known to be significantly more dynamic than in axons. Paclitaxel induced activating transcription factor 3 expression, a marker of neuronal stress/injury.
Introduction
Microtubule-targeted agents (MTAs) are commonly used to treat many types of cancer. MTAs are thought to combat tumor growth by altering the growing and shortening dynamics of microtubules (Giannakakou et al. 2002; Jordan and Wilson 2004) . Properly regulated microtubule dynamics are essential for intracellular transport mechanisms and cellular architecture. Disruption of these essential functions can lead to deleterious effects and even cell death (Argyriou et al. 2012; Fehrenbacher 2015; Field et al. 2014; Jordan and Wilson 2004; Poruchynsky et al. 2015) .
MTAs are generally delivered to patients systemically, exposing both tumor and non-tumor tissues to the chemical assault, which can lead to serious side effects including chemotherapy-induced peripheral neuropathy (CIPN) Electronic supplementary material The online version of this article (doi:10.1007/s12640-017-9729-6) contains supplementary material, which is available to authorized users. (Argyriou et al. 2012; Argyriou et al. 2014; Carlson and Ocean 2011; Grisold et al. 2012) . Though variable, approximately 30-40% of chemotherapy patients experience at least some CIPN symptoms including pain, hypersensitivity to pressure and hot or cold temperatures, tingling, burning sensations, numbness, and/or loss of deep tendon reflexes. These symptoms often begin in the distal extremities (i.e., fingertips and toes) and progress proximally up the arms and legs, suggesting that the longest nerves are most vulnerable (Argyriou et al. 2012; Carlson and Ocean 2011; Fehrenbacher 2015; Grisold et al. 2012; Windebank and Grisold 2008) . CIPN symptoms can be sufficiently severe as to necessitate dose reduction or treatment cessation, thereby being a significant impediment to favorable outcomes and quality of life (Argyriou et al. 2014; Carlson and Ocean 2011; Windebank and Grisold 2008) .
The onset, rate of progression, severity, and reversibility of CIPN symptoms vary greatly among different MTA treatments (Argyriou et al. 2012; Carlson and Ocean 2011; Grisold et al. 2012) . Different MTAs also vary in the frequencies at which they induce severe peripheral neuropathy. For instance, patients treated with paclitaxel tend to exhibit a higher frequency of severe CIPN than do patients treated with eribulin (Argyriou et al. 2012; Gradishar 2011) .
While all MTAs affect microtubule dynamics, the different classes of MTAs vary in their mechanisms of action. For example, the taxanes (e.g., paclitaxel) bind the inner surface of the microtubule lattice along its entire length and promote microtubule (MT) stability and suppression of MT shortening events, leading to net MT polymerization (Derry et al. 1995; Jordan et al. 2005 ). In contrast, eribulin binds selectively to the plus ends of MTs as well as to soluble tubulin subunits, preventing the addition of new subunits without affecting normal subunit loss and therefore lead to net MT depolymerization Smith et al. 2010) . Thus, although these two MTAs exhibit different molecular mechanisms of action, both alter the normal patterns of microtubule dynamics and compromise normal MT activities (Bunker et al. 2004; Jordan and Wilson 2004) . These observations have led us to hypothesize that the different mechanisms of action for different MTAs may underlie the variability in MTA-induced development, severity, and persistence of CIPN symptoms.
Given their importance, it is not surprising that cells invest considerable effort to properly regulate their microtubule dynamics using a variety of molecular mechanisms, including post-translational modifications, binding of microtubuleassociated proteins (MAPs), and altered tubulin isotype expression patterns. Alone or in combination, these mechanisms can provide highly tunable regulatory power (Bhattacharya et al. 2011; Janke and Bulinski 2011; Lu and Luduena 1993; Savage et al. 1989; Song and Brady 2015) . For example, acetylation of α-tubulin at lys-40 is a well-established marker of microtubule stability and recent work suggests that acetylation may itself actively confer MT stability (Dompierre et al. 2007; Godena et al. 2014; Janke and Bulinski 2011) . Additionally, a number of MAPs bind to microtubules and regulate their dynamics. For example, microtubule end binding proteins end binding protein 1 (EB1) and end binding protein 3 (EB3) bind selectively to the growing plus ends of microtubules, facilitating MT polymerization, directional cues, and cross-links to actin filaments (Akhmanova and Steinmetz 2015; Maurer et al. 2012; Geraldo et al. 2008; Gu et al. 2006; Jaworski et al. 2009 ). Finally, cells can regulate the relative expression levels of different tubulin isotypes to modify protofilament number or more subtle microtubule properties as well as relative susceptibility to stabilizing or destabilizing molecules (Bhattacharya et al. 2011; Lu and Luduena 1993; Savage et al. 1989) .The number and diversity of regulatory mechanisms support the notion of a tightly regulated microtubule network that is essential for survival and function of both dividing and post-mitotic cells. We have previously proposed that dysregulation of microtubule dynamics outside of a tolerable range can lead to severe deleterious effects for cells, including post-mitotic neurons (Bunker et al. 2004) .
A commonly held hypothesis for MTA-mediated action in post-mitotic neurons proposes that MTAs disrupt microtubule-based fast axonal transport, leading to deleterious downstream changes in axon biochemistry and subsequent neurodegeneration (Morfini et al. 2009 ). In vitro experiments in squid axoplasm, SKNSH neuroblastoma cell culture, and in vivo ligation models have all demonstrated that paclitaxel slows microtubule-based anterograde transport of organelles and proteins more potently than does eribulin (Lapointe et al. 2013; Smith et al. 2016) .
Recently, we have examined the morphological and microtubule-based biochemical effects of paclitaxel and eribulin upon sciatic nerve axons in a 2-week, maximum tolerated dose (MTD) mouse model of CIPN, a dosing strategy chosen to reflect current standard clinical practice (Benbow et al. 2016) . While both paclitaxel and eribulin exerted notable effects upon axon morphology and biochemistry, paclitaxel was markedly more disruptive of myelin morphology and induced more frequent signs of neurodegeneration than did eribulin treatment, consistent with recent work demonstrating paclitaxel's greater functional deficits in nerve conduction velocity and signal amplitude versus eribulin (Wozniak et al. 2011) . Treatment with either MTA also induced altered biochemistry of sciatic nerve axonal microtubules and microtubule-associated proteins. Remarkably, despite the fact that eribulin is traditionally viewed as a microtubule destabilizing drug based on short-term in vitro and cell culture exposure experiments, long-term treatment of mice with eribulin increased the abundance of axonal proteins indicative of microtubule growth and stability significantly more than did treatment with paclitaxel (Benbow et al. 2016 ). These observations suggested long-term cellular response mechanisms through which neurons may compensate for at least some of the deleterious effects of drugs upon their microtubule networks (Benbow et al. 2016) .
The cell bodies of long sensory axons of the sciatic nerve are located in the dorsal root ganglia (DRG), located just outside of the spinal cord. Although they are different compartments of the same cells, the long axons and cell bodies are highly specialized and distinct from one another in terms of structure and function. For example, axonal microtubules are more stable/less dynamic than cell body microtubules (Janke 2014; Song and Brady 2015) . It follows that cell bodies and axons may respond differently to stress and stimuli (e.g., chemotherapeutic assault). To test this notion, we conducted a detailed morphological and biochemical examination of MTA effects on DRG neuronal cell bodies to complement and extend our previous work. Overall, the effects of both drugs were much less marked in the cell bodies than in their axons. However, paclitaxel induced greater levels of neuronal stress and potentially deleterious changes to cell body biochemistry than did eribulin, which exhibited only minimal effects. Taken together, DRG neuronal cell bodies and their axons contain functionally distinct microtubule networks that exhibit unique biochemical responses to different MTA treatments. We hypothesize that the distinct mechanistic actions of paclitaxel and eribulin elicit different cellular and molecular responses, which may underlie the variability seen in the initiation, progression, persistence, and recovery from neuropathic symptoms.
Materials and Methods

Antibodies
Primary antibodies used in this study include anti-βIII-tubulin (Abcam, ab107216, 1:1000 dilution, (Rinkevich et al. 2014) ), anti-activating transcription factor 3 (ATF3) (C-19), (Santa Cruz SC-188, 1:1000 dilution, (Carozzi et al. 2013) ), anti-α-tubulin (Millipore, 04-1117, 1:100 dilution, (Zhang et al. 2011) ), anti-acetylated tubulin (Cell Signal, 5335, 1:800 dilution, (Creppe et al. 2009 )), anti-EB1 (Millipore, AB6057, 1:500 dilution, (Vitre et al. 2008) ), anti-EB3 (Santa Cruz, SC-101475, 1:200 dilution, (Levy et al. 1994) ), and antiphosphoneurofilament (Covance, SMI-31R, 1:2000 dilution, (Choi et al. 2008) ). Secondary antibodies used in this study included Cy2-conjugated donkey anti-rabbit (711-225-152), Cy2-conjugated donkey anti-rat (712-225-153), Cy3-conjugated donkey anti-chicken (703-165-155) , and Cy5-conjugated donkey anti-mouse (715-175-151) (all purchased from Jackson Immunoresearch, (West Grove, PA)).
Drugs
Eribulin mesylate (E7389, previously ER-086526 and NSC-707389) synthesized at Eisai Research Institute and stored at −80°in the dark was dissolved in 100% anhydrous DMSO (Sigma-Aldrich, St. Louis, MO) to produce a 10-mg/mL stock solution, which was separated into aliquots and stored at −80°C until day of administration. Each administration day, the stock solution was thawed and diluted with saline to a final concentration of 0.125 mg/mL in 2.5% DMSO/97.5% saline and administered in a 10-mL/kg volume. Paclitaxel (purchased from LC Laboratories, Woburn, MA, and stored at −20°C, in the dark) was dissolved in ethanol (100%) at 10% of final volume. An equal volume of cremophor (10% of final volume) was then added and the mixture re-vortexed for about 10 min. Immediately prior to injection, ice-cold saline was added to the final volume (as 80% of final) and the solution was maintained on ice during dosing. Dosing solutions of 3 mg/mL were made fresh daily and administered in a 10-mL/kg volume.
Animal Procedures
Female BALB/c mice (approximately 7-8 weeks old at onset of dosing) were obtained from Harlan Laboratories (Indianapolis, IN) and maintained with free access to water and a standardized synthetic diet (Harlan Teklab). Animal housing and procedure room temperature and humidity were maintained at 20 ± 2°C and 55 ± 10%, respectively. Artificial lighting provided a 12 h light/12 h dark cycle (light 7 am-7 pm). All experimental protocols were approved by the Institutional Animal Care and Use Committee of Johns Hopkins and adhered to all of the applicable institutional and governmental guidelines for the humane treatment of laboratory animals.
Mice were treated with a previously determined six-dose MTD regimen, administered intravenously every other day for 2 weeks with a 2-day rest period between weekly cycles (Wozniak et al. 2011) . MTD was defined as the maximal dose of eribulin mesylate or paclitaxel administered at which no more than one animal in the treatment group died spontaneously. In addition, this was the maximal dose tested at which no mice in the dose group required euthanasia due to >20% individual weight loss, showing overt clinical signs of distress or inability to eat and/or drink. The MTD dose, when administered IV six times on the above schedule, was determined to be 1.25 mg/kg (~3.75 mg/m 2 ) for eribulin and 30 mg/kg (90 mg/ m 2 ) for paclitaxel. The maximum tolerated dose model was chosen to reflect standard clinical practice in which physicians frequently dose human patients and results in mouse doses with similar orders of magnitude compared to human doses used clinically. For comparison, the current recommended dosing strategy for human patients for eribulin mesylate is 1.4 mg/m delivered by infusion over 2 to 5 min on days 1 and 8 of a 21-day cycle, whereas higher doses of paclitaxel (135 or 175 mg/ m 2 every three weeks) are commonly recommended (BristolMyers-Squibb 2011; Eisai-Inc 2016) . Additionally, the comparison of such different doses is supported by preclinical cell culture and in vivo experiments demonstrating a similarly large difference in the two drugs' doses and overall cytotoxicity profile (Towle et al. 2001) . These different doses highlight the fact that eribulin's potency (both anticancer efficacy and associated toxicities) occurs at significantly lower dose levels than those of paclitaxel. Xenograft doses of paclitaxel in ) and demonstrated a range of efficacious anticancer doses that included the eribulin dose used in Cortes et al. (2012) in humans (1.4 mg/m 2 ). Indeed, this differential is reflected in the FDA-recommended clinical dosing levels of the two drugs for breast cancer 1.4 mg/ m 2 for eribulin mesylate versus 135-175 mg/m 2 for paclitaxel. Twenty-four hours after receiving the last dose, animals from each treatment group underwent transcardial perfusion with paraformaldehyde 4% in 0.1 mM phosphate buffer, pH 7.4, for 10-15 min, while under deep anesthesia (10% chloral hydrate). L4-L5 DRG and left and right sciatic nerves at mid-thigh were dissected out from these mice. The specimens were fixed by immersion in 4% paraformaldehyde.
Tissue Sectioning
Fixed, whole dorsal root ganglia were cryo-protected at 4°C overnight in 30% sucrose (weight/volume) dissolved in PBS (1.37 M NaCl, 27 mM KCl, 100 mM Na 2 HPO 4 , 18 mM KH 2 PO 4 ) with 0.01% sodium azide. Tissue was embedded in Richard Allan Scientific Neg-50 frozen section medium (Thermo Scientific #6502) by freezing at −50°C. Sections were taken using a Microm HM560 cryostat (ThermoFisher Scientific, Waltham, MA) set to 16 μm thickness and thawmounted onto charged glass slides (two sections per slide). Slides were allowed to dry overnight prior to storage at −80°C.
Fixed whole sciatic nerves were processed as described previously (Benbow et al. 2016) . Briefly, sciatic nerves were embedded in 10% agarose (w/v) dissolved in 1× PBS with 0.01% sodium azide. Tissue was cross-sectioned distally to proximally in 100-μm sections using a Vibratome 1000 plus sectioning system. Sciatic nerve sections were collected in PBS and stored in 1× PBS with 0.01% sodium azide at 4°C until immunostaining.
Antibody Staining
Just prior to staining, DRG sections were thawed and dried. All blocking and antibody incubations and washes were performed at room temperature in stationary humid chambers. Sections were incubated in PBS-TritonX-100 (PBS-T) blocking agent (1× PBS, 0.1% TritonX-100, 1% BSA, 1% donkey serum) for 2 h, then overnight in primary antibodies diluted in PBS-T blocking agent. Two sections from each of the four treatment groups (vehicle paclitaxel, paclitaxel, vehicle eribulin, and eribulin) were stained simultaneously with the same antibody solution. Stained slides were mounted using ProLong Gold Antifade mounting media with DAPI (ThermoFisher Scientific). Slides were stored at 4°C prior to and after imaging.
Sciatic nerve sections were grouped so that one section from each treatment condition was stained with the same antibody solution. Antibodies were diluted to the same concentrations used in DRG staining in PBS-T block. Sections were incubated free-floating, at 4°C for 7 days to promote antibody penetration, washed three times in PBS-T (10 min each wash), and then incubated in secondary antibody for 2 days. Sections were then washed three times, 10 min each, as in the previous wash step and mounted onto glass slides with ProLong Gold Antifade mounting media with DAPI (ThermoFisher Scientific). Slides were stored at 4°C until imaging.
Image Acquisition
Images were collected on an Olympus Fluoview 1000 spectral confocal microscope equipped with 405, 488, 559, and 635 nm laser lines and photomultiplier tube detectors. Identical exposure settings (exposure time, laser intensity, offset, and gain) were used for sample groups treated with the same antibody solution by first identifying the brightest fluorescing sample within the treatment set. Each sample was imaged in 0.5-μm steps through 16-μm sample depth using sequential laser scanning with an Olympus PLANAPOSC 60× (1.40 NA) high refractive index oil immersion objective.
Image Analysis
Image analysis was performed using Imaris software version 7.5.2 (Bitplane, Zurich, Switzerland). Image Z-stacks were imported into Imaris software and rendered into threedimensional maximum-intensity projections for further analysis. All analyses were completed using three-dimensional projections to ensure retention and evenly account for fluorescence data of individual planes. Images acquired from sections stained with the same antibody solution, using the same exposure settings, were grouped as Bimage sets^for analysis (each group contained one section from each treatment condition; Figure S1 ) and received the same analysis parameters. For DRG analyses, regions of interest containing DRG cell bodies were manually selected to exclude tissue predominantly containing axons ( Figure S2 ). To assess relative levels of neuronal injury, Imaris software was used to quantitate the total number of nuclei per 10 4 μm 2 area of DRG tissue. The percent of ATF3-positive neuronal nuclei was counted manually. In order to quantify relative changes in fluorescence of proteins of interest (α-tubulin, acetylated-tubulin, EB1, and EB3) within DRG neurons, we further restricted the manually defined non-axonal DRG region, using anti-βIII-tubulin antibody staining to identify and mask neuronal cell bodies and identify neurons from other cell types present in the DRG. The mean fluorescent signal of a given protein of interest was calculated for a given section and three-dimensional region of βIII-tubulin-positive (neuronal) tissue, with each βIII-tubulin-positive volumetric pixel (voxel) contributing a fluorescence value for the protein in question. The normalization procedure is illustrated in Figure S3 . Raw fluorescence values for the protein of interest within βIII positive regions were collected and averaged over a given section producing the Btreatment mean.^Treatment means were normalized by dividing the section mean of one treatment by the sum of treatment means of that image group. This method was employed to retain the natural variability within vehicle treatment conditions. This was the same methodology used previously (Benbow et al. 2016 ).
Statistical Analysis
One-way ANOVAs with post hoc Tukey's tests were employed to test the statistical significance between differences in the means of treatment groups in all instances unless otherwise noted (*p < 0.05, **p < 0.01, ***p < 0.001). In cases in which the variances between conditions were statistically different, Bonferroni corrected Student's T tests for multiple comparisons were employed (*p < 0.0167, **p < 0.003, ***p < 0.0003). n = 5 for all DRG analyses except EB1, which was n = 4. Sciatic nerve tissue from three mice for each treatment condition was analyzed for relative levels of βIII-tubulin (n = 3). Error bars within graphs represent the standard error of the mean (SEM).
Results
Paclitaxel but Not Eribulin Increases the Abundance of ATF3-Positive Nuclei
ATF3 is commonly used as a marker for neuronal injury and stress (Carozzi et al. 2013; Tsujino et al. 2000) . The percent of ATF3-positive nuclei in the DRG of 2-week paclitaxel-, eribulin-, or vehicle-treated mice was quantitated by counting the number of ATF3-positive neuronal nuclei as compared to the total number of neuronal nuclei present. The mean percent of ATF3-positive neuronal nuclei increased significantly in DRG tissue from paclitaxel but not eribulin-treated mice compared to their respective vehicle controls, (Fig. 1a, b) . Paclitaxel-treated DRG contained an average of 49.8 ± SEM 8.7% of neuronal nuclei expressing ATF3, whereas very few ATF3-positive nuclei were seen in the tissue from mice treated with the vehicle for paclitaxel (0.3 ± 0.3%, p < 0.001).
Eribulin treatment led to a small but not statistically significant (p > 0.05) increase in ATF3-positive nuclei (13.9 ± 3.1%) relative to the vehicle for eribulin. The difference between paclitaxel treatment and eribulin treatment was statistically significant (p < 0.01).
As an increase in non-neuronal cells within nerve tissue can also indicate nerve injury (Janes et al. 2014; Peters et al. 2007a; Peters et al. 2007b; Rotshenker 2011; Zhang et al. 2016) , we sought to assess whether DRG would exhibit an increase in non-neuronal cells after a 2-week MTD drug treatment. Since DRG neurons are post-mitotic in adult mice, any increase in the number of DRG nuclei would be the result of an increased number of non-neuronal cells. Therefore, we quantified the total number of nuclei present per 10 4 μm 2 DRG tissue, as indicated by DAPI staining. Neither paclitaxel nor eribulin nor their vehicle treatments led to any significant change in the mean number of nuclei per 10 4 μm 2 area of DRG tissue, with observed means of 105 ± SEM 4.3, 108.3 ± 7.8, 113.4 ± 8.7, and 118 ± 3.8 nuclei for vehicle paclitaxel, paclitaxel, vehicle eribulin, and eribulin, respectively (Fig. 1b, c) .
Paclitaxel but Not Eribulin Alters Microtubule Biochemistry in DRG Neuronal Cell Bodies
We next examined changes to the tubulin composition in the DRG between paclitaxel-, eribulin-, and vehicle-treated mice, using anti-α-tubulin, anti-βIII-tubulin, and anti-acetylatedtubulin antibodies. Total tubulin content, as indicated by anti-α-tubulin fluorescence, was not significantly different in DRG neuronal cell bodies treated with either drug relative to its vehicle (Fig. 2a, b) . Mean fluorescent signals observed were 22.5 ± SEM 2.3 arbitrary fluorescence units (A.U.s) for vehicle paclitaxel, 22.8 ± 2.1 for paclitaxel, 26.1 ± 1.0 for vehicle eribulin, and 28.7 ± 1.7 for eribulin (p > 0.05). In contrast, the abundance of βIII-tubulin increased approximately 1.3-fold from a mean of 21.6 ± 0.6 A.U.s observed in the DRG neuronal cell bodies from vehicle paclitaxeltreated mice to 28.9 ± 1.0 observed in the DRG neuronal cell bodies from paclitaxel-treated mice (p < 0.001, when paclitaxel is compared to its vehicle, and p < 0.05 when paclitaxel is compared to eribulin, Fig. 3a) . These data are consistent with the paclitaxel-mediated induction of βIII-tubulin in cultured cancer cell lines Ranganathan et al. 1996) . In contrast, eribulin treatment did not induce a significant change of βIII-tubulin levels from the vehicle control condition (24.0 ± 0.7 compared to 25.5 ± 0.1, respectively (p > 0.05, Fig. 3a, b) .
As changes to levels of βIII-tubulin in sciatic nerve in response to chemotherapy treatment were not explored in our previous study, we examined sciatic nerve tissue immunostained for βIII-tubulin within the current set of experiments to enable their comparison. Surprisingly, our results demonstrated that both paclitaxel and eribulin treatment modestly reduced axonal βIII-tubulin levels within sciatic nerve tissue (Fig. 3c, d ). The mean fluorescent signals from axonal βIII-tubulin in paclitaxel and eribulin-treated mice (23.5 ± SEM 0.7 and 21.6 ± 0.8, respectively) were statistically different compared to the mean levels of axonal βIII-tubulin signal in mice treated with their respective vehicles (29.0 ± 0.4 for vehicle paclitaxel; p < 0.01, 25.9 ± 1.0 for vehicle eribulin, p < 0.05, Fig. 3c, d ). There was no statistically significant difference between paclitaxel and eribulin means (p > 0.05), indicating a similar degree of effect with each drug. While both drugs altered levels of axonal βIII-tubulin, there was no statistical difference in mean axonal βIII-tubulin levels between paclitaxel and eribulin treatments.
Acetylation of α-tubulin at lysine 40 is a well-established marker for microtubule stability, as acetylation has been observed most commonly in long-lived microtubules (Black and Keyser 1987; Janke and Bulinski 2011; Webster and Borisy 1989) . We used anti-acetylated-tubulin immunostaining to assess the relative levels of acetylated tubulin as an indication of the stability of the microtubule network within the cell bodies of sciatic neurons. Paclitaxel treatment significantly increased the relative level of acetylated tubulin 1.9-fold from 21.1 ± SEM 2.2 in the DRG neurons from the mice treated with the paclitaxel vehicle control to a mean fluorescence of 41.7 ± 3.3 observed in the DRG neurons from paclitaxeltreated mice (p < 0.001¸Fig. 4a, b). Eribulin on the other hand did not alter the levels of acetylated tubulin significantly as compared to treatment with its vehicle control. The mean level of acetylated tubulin for paclitaxel treatment was also statistically different from the mean level of acetylated tubulin observed in eribulin treatment (20.7 ± 2.4 A.U.s, p < 0.001, Fig. 4a ).
Paclitaxel but Not Eribulin Increases the Level of EB1, but Not EB3, in DRG Neuronal Cell Bodies
As a marker for growing microtubules, we next assessed the abundance of the microtubule end binding proteins EB1 and EB3. DRG from paclitaxel-treated mice exhibited a 2.0-fold difference in mean fluorescent signal of 35.4 ± SEM 0.8 as compared to the vehicle control for paclitaxel (17.5 ± SEM 1.7, p < 0.001, Fig. 5a, b) . In contrast, eribulin treatment did not result in a statistically significant change in EB1 signal as compared to its vehicle control (26.1 ± 1.9 and 21.1 ± 1.8, On the other hand, EB3 immunostaining revealed no changes in EB3 abundance as a result of either MTA treatment (p > 0.05, Fig. 5c, d ) relative to their corresponding vehicle controls. DRG tissue from paclitaxel-treated mice showed a mean fluorescent signal of 24.8 ± SEM 1.7 and eribulin demonstrated a mean signal of 25.5 ± 2.6 whereas the vehicle for paclitaxel and the vehicle for eribulin demonstrated means of 21.6 ± 1.8 and 28.3 ± 2.1, respectively.
Discussion
In an effort to better understand the underlying mechanisms of CIPN, we sought to investigate MTA-induced effects upon the microtubule network of sensory nerve cells. Our specific goal was to test the hypothesis that MTAs possessing different mechanisms of action differentially affect neuronal cell bodies and axons of the sciatic nerve. We have examined MTA effects on sciatic nerve axons (Benbow et al. 2016 ) and their DRG cell bodies (here), allowing compartmental comparison of effects and providing novel insights to MTA-induced peripheral neuropathy.
Paclitaxel Induces Greater Neuronal Stress than Eribulin, Correlating with More Severe Morphological Disruptions
Our previous work examining 2-week maximum tolerated dose effects of MTAs on sciatic nerve axons revealed that paclitaxel induced nerve fiber collapses with greater frequency than did eribulin (Benbow et al. 2016) . This led us to ask in the current work if MTA-induced effects of neuronal injury or stress would be evident in the corresponding DRG cell bodies after similar drug treatment. Using ATF3 expression as a marker for neuronal stress (Carozzi et al. 2013; Tsujino et al. 2000) , the data demonstrate that paclitaxel but not eribulin induces a significant increase in the percentage of neuronal nuclei exhibiting ATF3 expression, suggesting neurons experience greater stress upon paclitaxel treatment compared to eribulin treatment.
Paclitaxel and Eribulin Differentially Affect Peripheral Neuron Cell Bodies and Axons
As noted above, paclitaxel induces a significantly higher frequency of severe CIPN than does eribulin. Consistent with this observation, paclitaxel induces more frequent morphological abnormalities and signs of neurodegeneration than does eribulin in our preclinical 2-week MTD experiments on mouse sciatic nerves (Benbow et al. 2016) . Biochemically, both paclitaxel and eribulin induced large increases in total tubulin abundance and tubulin acetylation, with eribulin mediating even larger inductions than paclitaxel (summarized in Table 1 ). Importantly, large increases in tubulin concentration and acetylated tubulin abundance are both likely to promote microtubule growth and stabilization. Given that axons require a relatively stable microtubule network to conduct axonal transport and to maintain morphological stability, we hypothesized that the stronger eribulin-mediated increase in the axonal microtubule network might counter the deleterious effects of eribulin more effectively than paclitaxel's stabilizing effects might counter its deleterious effects. In the current work, we have extended our earlier axonal work by comparing the effects of paclitaxel and eribulin in the dorsal root ganglia cells that are the neuronal cell bodies of the sciatic nerve sensory axons. Many of the biochemical effects of the two drugs were quite different than observed in the axons. Neither drug affected total tubulin levels, although paclitaxel induced a slight increase in the levels of βIII-tubulin (Figs. 2 and 3 , Table 1 ). Paclitaxel also increased the level of acetylated tubulin~twofold, whereas eribulin had no effect (Fig. 4, Table 1 ). Similarly, paclitaxel treatment induced the levels of EB1 by~twofold, whereas eribulin treatment had no significant effect (Figs. 4 and 5, Table 1 ). Thus, paclitaxel but not eribulin induces both biochemical changes and neuronal stress upon cell bodies. Further, paclitaxel affects tubulin biochemistry in a manner suggesting increased microtubule stabilization, although this effect is quantitatively much smaller than that observed in the axons. On the other hand, eribulin had essentially no detectable morphological or biochemical effects in the cell bodies, again in contrast to its marked effects in axons.
Regionally Specific Effects of MTAs May Underlie the Development of CIPN
Peripheral sensory nerve axons can span enormous distances and possess multiple distinct regions with distinct functions. For example, these cells receive signals at their distal axon terminals in the periphery, then must propagate the signal along the entire length of their peripheral axon branch, bypassing the cell body and eventually relaying the signal along the central branch axon to the next cell in the circuit in the spinal cord. Consistent with the notion of region-specific functions, the microtubule network differs markedly with respect to tubulin isotype composition, tubulin posttranslational modification, and association with various microtubule-associated proteins, thereby creating regionally and functionally distinct microtubule networks (Gundersen et al. 1987; Janke and Bulinski 2011; Song and Brady 2015) . For example, axonal microtubules are enriched in acetylated and detyrosinated tubulin, indicating a high degree of stability, whereas microtubules in neuronal cell bodies have far lower concentrations of these tubulin modifications suggesting greater dynamicity (Janke and Kneussel 2010; Song and Brady 2015) . This translates into distinct functionalities as axons require stable microtubules to mediate axonal transport over long distances, while functions in the cell body necessitate a more dynamic cytoskeletal network. Based on these observations, we predict that different MTAs may differentially affect microtubule action within a cell based on their regionally and functionally defined properties. Biochemically, both paclitaxel and eribulin treatment induced large increases in total tubulin abundance and tubulin acetylation in axons, and the eribulin-mediated inductions were even larger than the paclitaxel inductions. These increases in tubulin and acetylated tubulin abundance are both likely to promote microtubule growth and stabilization. Given that axons require a relatively stable microtubule network to conduct axonal transport and to maintain morphological stability, we hypothesized that the more robust eribulin-mediated increase in the axonal microtubule network might serve to promote axonal transport and maintain axonal morphology. In contrast, microtubules in cell bodies are relatively dynamic (i.e., less stable) (Janke 2014; Song and Brady 2015) . The suggestion here that paclitaxel but not eribulin promotes increased microtubule stability in cell bodies that require more dynamic and less stable microtubules together with greater neuronal stress as indicated by ATF3 expression leads to the model that these actions of paclitaxel may be detrimental. Taken together with our earlier work (Benbow et al. 2016) , we suggest that paclitaxel deleteriously alters microtubule biochemistry in both cell bodies and axons and speculate that these changes in microtubule biochemistry may contribute to the differential frequency of severe CIPN observed in clinics. Functional studies will be necessary to assess the validity of this model.
MTA Exposure and CIPN Induction
Another important issue to consider with respect to the differential induction of severe CIPN by paclitaxel versus eribulin is the possibility that the two drugs are taken up differentially by peripheral sensory neurons. In other words, might the apparent reduction in eribulin-mediated neuropathic events be the result of reduced exposure of peripheral neurons to eribulin as compared to paclitaxel? In this regard, recent work demonstrates that eribulin actually has greater penetration and retention in dorsal root ganglia and axons of peripheral neurons than does paclitaxel ).
Summary
Taken together with our earlier work (Benbow et al. 2016) , we have shown that eribulin-induced effects are localized to axons, leaving the microtubule network within cell bodies generally unperturbed. In contrast, paclitaxel has significant effects in both DRG neuronal nuclei and axons. Previously, we had hypothesized that the effects observed with eribulin treatment in sciatic nerve axons ultimately led to an advantageous strengthening of the microtubule network within axons. We now additionally hypothesize that eribulin results in less severe microtubule network alteration in the neuronal cell bodies in the DRGs that are connected to the sciatic nerve axons than does paclitaxel, which may also contribute to differential induction of CIPN. Ongoing investigations aim to test this hypothesis mechanistically in in vitro, cell culture, and animal models.
